Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Pfizer’s COVID-19 Pill Up for PAFSC Review on Feb. 10
February 4, 2022
-
REGULATORY 9 Drugs/6 APIs for Fertility Treatment to Be Listed in April; Generics Listing in June at the Earliest: Chuikyo
February 3, 2022
-
BUSINESS 650 Astellas Staffers Choose Voluntary Redundancy, Sales Force Down to 1,200
February 3, 2022
-
REGULATORY DPO Opted Not to Apply 80% Pricing Rule for Vynmac for Clinical Benefits: Minutes
February 2, 2022
-
BUSINESS Sumitomo Dainippon Expects to Get Back on Growth Track in FY2025 after Latuda’s LOE: President
February 2, 2022
-
REGULATORY Japan Finalizes Deal for Pfizer’s COVID-19 Pills, Eyes Approval by Mid-February
February 1, 2022
-
REGULATORY Japan Won’t Give 3rd-Shot Approval for Shionogi’s Jab with Booster Trial Alone
February 1, 2022
-
ORGANIZATION Japan Market Should Grow in Single-Digit Range, Not Zero Growth: PhRMA Chair
January 31, 2022
-
REGULATORY MHLW Sets Volume Thresholds for Drug Orders to Resolve Generic Shortages
January 28, 2022
-
BUSINESS Flatiron Health Joins Hands with National Cancer Center to Start Up Japan Biz
January 27, 2022
-
BUSINESS Nippon Shinyaku Snags US Commercial Rights to Capricor’s DMD Cell Therapy
January 26, 2022
-
REGULATORY PMDA to Place Top Priority on Safety Measures under Proposed Emergency Approval System: Chief Executive
January 25, 2022
-
BUSINESS Novartis Downsizing Tokyo Head Office to Cut Costs and Support Diverse Work Styles
January 24, 2022
-
REGULATORY Pfizer’s Comirnaty Bags Japan Approval for Ages 5-11; Actemra OK’ed for COVID-19
January 21, 2022
-
REGULATORY Pfizer’s Comirnaty Clears Key Panel for Ages 5-11; Actemra Set for COVID-19 Nod
January 21, 2022
-
REGULATORY Macroeconomic Indexing Lacks Perspectives to Promote Innovation, Improve Care: MHLW Bureau Chief
January 20, 2022
-
REGULATORY Re-Pricing to Hit 23 Drugs in April; Takecab, GLP-1s, Vyndaqel/Vynmac, and More
January 19, 2022
-
REGULATORY Takecab Faces 2nd “Huge-Seller” Price Slash, All GLP-1 Injectables to Get Cut Too on Market Expansion
January 18, 2022
-
COMMENTARY Significance and Challenges around Proposed Emergency Approval Scheme, Eyes on Diet Debate
January 17, 2022
-
BUSINESS Pfizer Files Oral COVID-19 Pill in Japan
January 14, 2022
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…